

+ Access to Medicine Index

-
- + *Access to Medicine Index*
 - + *Access to Nutrition Index*
 - + *Carbon Disclosure Project (CDP)*
 - + *Climate Bonds Initiative (CBI)*
 - + *Global Reporting Initiative (GRI)*
 - + *Corporate Human Rights Benchmark (CHRB)*
 - + *Impact Measurement Project (IMP)*
 - + *Platform Carbon Accounting Financials (PCAF)*
 - + *Platform Living Wage Financials*
 - + *SDG Impact Measurement*
 - + *Sustainable Accounting Standards Board (SASB)*
 - + *TCFD*
 - + *Vastgoedtools:*
 - + *Bewuste Bouwers*
 - + *BREEAM*
 - + *Energielabels*
 - + *GRESB*

04.01

ACCESS TO MEDICINE INDEX (1/2)

Door: Opgericht in 2003 door de Nederlandse ondernemer Wim Leereveld, sinds 2015 geleid door Executive Director Dr. Jayasree K. Iyer. [\[Bron\]](#)

Sinds:	2003 Access to Medicine Foundation opgericht
	2008 Publicatie van de eerste Access to Medicine Index, sindsdien iedere twee jaar
	2017 Publicatie van de eerste Access to Vaccines Index
	2018 Publicatie van de eerste Antimicrobial Resistance Benchmark

Gebied: Social

Verplichting: Nee, **Vrijwillig.**

Gebaseerd op: "It started with a single idea: how can we encourage the pharmaceutical industry to do more to help the world's poorest people access the medicine they need?" [\[Bron\]](#)

Informatie:  "In 2008, this list formed the basis of the first Access to Medicine Index, **ranking 20 of the world's largest pharmaceutical companies on their policies and practices for improving access to medicine**. It was the first Index to focus on a specific industry sector and topic related to corporate social responsibility. The Access to Medicine Index has been published every two years since 2008. In addition to publishing the Index, the Access to Medicine Foundation has gone on to expand its research programmes to include analyses of access to vaccines and the pharmaceutical industry's efforts to address antimicrobial resistance." [\[Bron\]](#)

Zie FAQ: <https://accesstomedicinefoundation.org/frequently-asked-questions>

Zie alle publicaties: <https://accesstomedicinefoundation.org/publications>

- Rapport '**Access to Medicine Index 2018**' (november 2018):
<https://accesstomedicinefoundation.org/publications/2018-access-to-medicine-index>
- Rapport '**Access to Vaccines Index 2017**' (maart 2017):
<https://accesstovaccinesindex.org/>
- Rapport '**2018 Antimicrobial Resistance Benchmark**' (januari 2018):
<https://accesstomedicinefoundation.org/publications/2018-antimicrobial-resistance-benchmark>

ACCESS TO MEDICINE INDEX (2/2)

Gerelateerd:



Pagina voor investeerders: <https://accesstomedicinefoundation.org/about-us/investors>

"Investors and analysts use the Access to Medicine Index in multiple ways:

- Integrate companies' scores and ranking positions into quantitative stock valuation models and/or proprietary sustainability frameworks.
- Use the methodology of the Access to Medicine Index to identify quantitative indicators ("red flags" or "positive signals") which can be integrated into the systematic analysis of the whole pharmaceutical and biotechnology industry.
- Interact regularly with the Foundation to obtain unique and tailored analysis deemed material to the long-term profitability of individual pharmaceutical companies." [\[Bron\]](#)

Gefinancierd door Nederlandse ministeries (BuZa en VWS), Nationale Postcode Loterij, UK Aid en de Bill & Melinda Gates Foundation.

Leden/deelnemers:

Investor Statement Access to Medicine Index

Ondersteund door o.a. (Nederlandse) pensioenfondsen, pensioenuitvoeringsorganisaties, vermogensbeheerders, banken, verzekeraars.

Zie: <https://accesstomedicinefoundation.org/about-us/investors>

Wat doen pensioenfondsen? (1/2)

Pensioenfonds Detailhandel

- 'We zullen ook in de toekomst farmabedrijven blijven stimuleren de good practices over te nemen die uit de (red. access to medicine) index naar voren komen. Ook blijven we de sector aanspreken op verantwoorde prijsstelling van medicijnen, ook in ontwikkelde landen. Dit onderwerp krijgt steeds meer aandacht in Nederland, waarbij zelfs de Minister van VWS (Volksgezondheid) Novartis heeft aangesproken op zijn prijsbeleid.' [\[Bron\]](#)

Links:

<https://accesstomedicinefoundation.org/>